Analyst Price Target is $6.50
▲ +126.48% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for VistaGen Therapeutics in the last 3 months. The average price target is $6.50, with a high forecast of $9.00 and a low forecast of $5.00. The average price target represents a 126.48% upside from the last price of $2.87.
Current Consensus is
The current consensus among 5 investment analysts is to buy stock in VistaGen Therapeutics. This Buy consensus rating has held steady for over two years.
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.